Skip to content

A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format

A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00780468
Enrollment
134
Registered
2008-10-27
Start date
2008-10-31
Completion date
2009-07-31
Last updated
2014-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

Weight loss, Diet, Obesity

Brief summary

This study will provide data on two systems for assigning point values to food choices in a diet plan. The primary purpose of this study is to compare the effectiveness of the two systems with regard to changes in body weight.

Interventions

BEHAVIORALExisting diet plan
BEHAVIORALNew diet plan

Sponsors

WW International Inc
CollaboratorINDUSTRY
Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female 25-65 years of age inclusive * Body Mass Index (BMI) 27.0 -35.0 inclusive. * Not currently taking a prescription medication for weight loss (e.g. orlistat (Xenical), sibutramine (Meridia), phentermine). * Not currently taking any over-the-counter weight loss medications or supplement(s). * Not currently enrolled in commercial weight loss program (e.g. Jenny Craig, Weight Watchers) or self-help group (e.g. TOPS, Overeaters Anonymous). * Willing and able to commit to regular physical activity (e.g. walking) five days per week as required by study protocol. * Willing to keep and turn in a daily log/compliance book at the times required by study protocol. * Willingness and ability to make all scheduled appointments at MUSC as required by study protocol. * Willingness to make weekly meetings at MUSC.

Exclusion criteria

* History of thyroid disease, but not taking medication, or medication dosage changed one or more times over last 6 months. History of thyroid disease and on a stable dose of prescription medication for 6 months or longer is acceptable. * Diagnosed with Type I or Type II diabetes or glucose intolerance, or use of anti-diabetic medications * History of a surgical procedure for weight loss at any time (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve). * History of major surgery within three months of enrollment. * History of heart problems (e.g. angina, bypass surgery, MI, etc.) within three months prior to enrollment. * Presence of implanted cardiac defibrillator or pacemaker. * Uncontrolled hypertension/high blood pressure. * Orthopedic limitations that would interfere with ability to engage in regular physical activity. * Gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea or active gallbladder disease. * History or presence of cancer. Persons with successfully resected basal cell carcinoma of the skin may be enrolled if treatment completed more than 6 months prior to enrollment. * History of clinically diagnosed eating disorders including anorexia nervosa or bulimia nervosa. * Women who are pregnant, lactating , trying to become pregnant or unwilling to use an effective means of birth control. * Participation in another clinical trial within 30 days prior to enrollment. * Weight loss of more than 5 pounds for any reason over the 30 days prior to enrollment. * Taking any psychotropic medicine known to influence weight or weight loss

Design outcomes

Primary

MeasureTime frame
Change in bodyweight.12 weeks

Secondary

MeasureTime frame
Changes in waist circumference, blood pressure, lipids, questionnaire measures12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026